Dr Ashwin Jainarayanan, who last year completed his DPhil studies in Professor Mike Dustin\u2019s research group, has been named in the Forbes 30 Under 30 Europe list in Science and Healthcare (2025). Based on his DPhil work, Ashwin co-founded the company Granza Bio in 2024 alongside Dr. Ashwin Nandakumar and Prof Mike Dustin.
New research from the Kennedy Institute has revealed how two important proteins, TBK1 and IKKe, play a crucial role in preventing premature cell death, which can lead to serious inflammation in the body. The findings are particularly relevant for people with a mutation in the TBK1 gene who often develop multiorgan inflammation caused by excessive cell death even in the absence of any infection.
Researchers at the Kennedy Institute have developed a new computational framework that allows simultaneous analysis of gene expression and mechanical forces within cells and tissues, uncovering insights into how the interplay between transcriptional and mechanical signals guides processes such as cell fate decisions or the formation of spatially distinct tissue compartments.
Study shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
The\u202fAmerican Association of Immunologists (AAI)\u202fhas recognised the outstanding work of the Kennedy Institute\u2019s Professor of Molecular Immunology Michael Dustin\u202fby naming him a Distinguished Fellow of AAI.
A new study conducted by researchers at the Kennedy Institute of Rheumatology has uncovered a pivotal role of asparagine metabolism in regulating B cell homeostasis and immune response.
Paul joined the Kennedy Institute in September 2024 as part of the Newton-Abraham Visiting Professorship, a prestigious award given by the University of Oxford to the most distinguished scholars in the biological, chemical or medical sciences.
The Kennedy Institute of Rheumatology, together with the nearby Institute of Developmental and Regenerative Medicine (IDRM), hosted an Open Day on 25th October for prospective DPhil students. The event provided an exciting opportunity for potential applicants to get an idea of what it would be like to do a DPhil at Oxford.
In a world first, researchers at the Kennedy Institute, Oxford have mapped the cellular dynamics following treatment with the most commonly used advanced therapy in autoimmune diseases. They have discovered why some patients benefit from this therapy while others do not, potentially paving the way for new therapies.
A perspectives piece published in the Proceedings of the National Academy of Sciences (PNAS) sheds light on the importance of mechanical forces in the early activation of T cells, a critical part of the immune response.
This August, the annual \u2018From the Laboratory to the Clinic\u2019 conference celebrated 25 years since the first biological therapies were approved for rheumatoid arthritis. The conference brings together a global audience of clinicians and academic and industrial scientists, facilitating discussions to bring novel treatments from bench to bedside.
Dr Kate Coldwell has joined the Oxford Centre for Microbiome Studies at the Kennedy Institute to study the links between liver disease and gut bacteria, having been awarded the Daphne Jackson Fellowship, co-funded by the Kennedy Trust for Rheumatology Research (KTRR) and the Medical Research Council.
Professor Sir Ravinder Maini and Professor Sir Marc Feldmann have jointly received The Royal Society\u2019s Royal Medal (Applied) for inventing anti-TNF therapy to treat rheumatoid arthritis (RA), bringing it from bench to bedside in one of the biggest success stories of modern medicine.
The Kennedy Institute retreat took place in July 2024 at the Sa\u00efd Business School, Oxford. Over two jam-packed days, attendees met new colleagues, learned about scientific advances and of course, had fun!
A new microscopy technique, developed by researchers at the Kennedy Institute, enables detailed analysis of molecular interactions in live cell membranes, overcoming previous limitations in sensitivity and accessibility.
The Kennedy Institute at the University of Oxford recently hosted a dinner to celebrate and thank the Kennedy Trust for Rheumatology Research for its generous support and the endowment of two new professorships in translational medicine at the Institute.
The Oxford Microbiome Network (OMiN) aims to facilitate collaborations, knowledge sharing, and access to resources for microbiome researchers across Oxford. OMiN is co-led by researchers in the Kennedy Institute of Rheumatology and the Department of Biology. The network officially launched on 20th May 2024 with an event at Keble College.
Alan has spent two months at the Kennedy Institute as a guest of Professor Dame Fiona Powrie. During his visit he has spent his time collaborating with researchers at the Kennedy and other departments in the University, and mentoring young investigators on their career development.
![\"\"](\"https://www.kennedy.ox.ac.uk/news/dr-ashwin-jainarayanan-named-in-forbes-30-under-30/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n